Tirzepatide vs Retatrutide: How the Research Compares

Tirzepatide and Retatrutide are two of the most actively studied peptides in metabolic research, and the key difference between them is simple: how many receptors they engage.

Tirzepatide: a dual agonist

Tirzepatide acts on the GLP-1 and GIP receptors, two gut-hormone pathways central to glucose and appetite research. Engaging both at once is what made it a major focus in the metabolic literature.

Retatrutide: a triple agonist

Retatrutide adds a third receptor, glucagon, to those same two. That extra pathway is what sets it apart in the research, where it is studied for its role in glucose regulation, appetite signalling and lipid and body-composition pathways.

Why they get compared

The two are frequently compared in research models precisely because they share a backbone but differ by that one added pathway. It makes them a clean way to study what the glucagon receptor contributes on top of GLP-1 and GIP.

Supplied strictly for laboratory research use only. Not for human or veterinary consumption, medical use, or diagnostic purposes. No outcome, benefit or dose is implied.